Curevac B.V. Stock Price, News & Analysis

CureVac N.V. (Nasdaq: CVAC) announced promising preclinical data for its COVID-19 vaccine candidate, CVnCoV, demonstrating protection against the SARS-CoV-2 variant B.1.351 (South African variant) in transgenic mice. The study showed that CVnCoV induced robust antibody responses, achieving full protection (100% survival) against both the original virus and the variant strain following a two-dose vaccination schedule. The vaccine effectively blocked viral replication in infected mice, underscoring its potential in combating emerging SARS-CoV-2 variants.

CureVac (Nasdaq:CVAC) is enhancing its late-stage clinical trials for its COVID-19 vaccine candidate, CVnCoV, in response to new variants. The pivotal HERALD Phase 2b/3 trial will now include select strains for a case-driven analysis. Additionally, a protocol amendment for the Phase 2a trial in older adults will add a secondary efficacy endpoint. CureVac aims for market authorization by Q2 2021 and anticipates data readouts from both trials in the same quarter.

CureVac and Novartis have signed an initial agreement for the manufacturing of CureVac's COVID-19 vaccine candidate, CVnCoV. Production is set to begin in Q2 2021, aiming for up to 50 million doses by the end of 2021, and an additional 200 million doses in 2022 at Novartis' Kundl site in Austria. This collaboration enhances CureVac's European manufacturing network, expected to boost capacity significantly. The agreement is part of CureVac's ongoing development of mRNA-based vaccines initiated in January 2020, with prior successful clinical trials.

CureVac N.V. (NASDAQ:CVAC) announced its participation in two upcoming virtual investor conferences: the Leerink 10th Annual Global Healthcare Conference on February 24, 2021, at 8:00 am EST, and the Credit Suisse 2021 London Global Healthcare Conference on March 2, 2021, at 12:00 pm GMT / 7:00 am EST. Interested parties can find event details and access presentation materials on CureVac's Investor Relations page. The company, based in Tübingen, Germany, specializes in mRNA technology, with over 20 years of experience.

CureVac announced the initiation of a rolling submission with the European Medicines Agency (EMA) for its CVnCoV COVID-19 vaccine, currently in late-stage trials. The submission began with pre-clinical data that successfully passed technical validation. This process aims to streamline marketing authorization during the public health emergency. The HERALD trial is assessing CVnCoV in healthy adults across Europe and Latin America. CureVac emphasizes the potential of its mRNA technology in combating COVID-19 and highlights ongoing expansions in manufacturing capacity.

CureVac N.V. (NASDAQ:CVAC) is hosting a conference call on February 5, 2021, at 4:00 p.m. CET / 10:00 a.m. EST to discuss updates regarding its COVID-19 partnership. Interested participants can join via dial-in numbers or through a live webcast available on the CureVac website. The company is recognized for its innovative mRNA technology with over 20 years of expertise, focusing on developing treatments across various medical fields, including vaccines and cancer therapies. The call intends to outline future business strategies and updates on clinical developments.

CureVac N.V. (CVAC) announced a collaboration with the UK Government to develop and manufacture variant vaccines targeting SARS-CoV-2. The aim is to produce 50 million doses, pending regulatory approval, to mitigate current pandemic effects and prepare for future outbreaks. This partnership leverages CureVac's mRNA technology and the UK’s Vaccine Taskforce expertise. The collaboration involves rapid assessment of multiple variants, with a focus on expediting clinical trials in the UK. CureVac is also working with Bayer and GlaxoSmithKline on its existing COVID-19 vaccine, CVnCoV, currently in Phase 3 trials.

CureVac N.V. (NASDAQ:CVAC) has initiated an expansion of its ongoing Phase 1 trial for CV8102, an RNA-based cancer treatment, focusing on advanced melanoma. The selected dose of 600µg aims to confirm the drug's safety, tolerability, and efficacy. Initial results have shown promising immune responses in patients, with the upcoming trial enrolling 30 patients with PD-1 refractory melanoma. The study will provide further insights into CV8102's mechanism and its potential as a new form of cancer therapy.

CureVac (NASDAQ:CVAC) announced that underwriters of its public offering, which closed on February 1, 2021, fully exercised their option to purchase an additional 750,000 common shares at $90.00 per share. This brings the total shares sold to 5,750,000, generating approximately $517.5 million in gross proceeds before expenses. BofA Securities, Jefferies, and Evercore ISI managed the offering, which was registered with the SEC on January 27, 2021. The additional capital enhances CureVac's capabilities in mRNA technology and its clinical pipeline.